Edison Scientific Inc.

Edison Scientific Inc. is a United States-based artificial intelligence company headquartered in San Francisco, California. It builds AI software for scientific research and development, marketed under the product name Kosmos, which the company describes as "The AI Scientist for R&D." The platform is positioned to accelerate the full lifecycle of research and development, from hypothesis generation through regulatory approval, and is aimed at biopharma organizations and academic institutions. Edison Scientific's core offering, Kosmos, is designed to drive scientific investigations autonomously. According to the company, it reads literature, analyzes data, generates hypotheses, steers investigations mid-run, branches hypotheses, and executes scientific workflows. It is intended to support the full lifecycle of drug development, executing workflows from target identification through clinical development and filing. The platform is also designed to embed in scientists' existing workstreams, collaborating through tools such as Slack, Teams, and email while advancing investigations and surfacing findings. A distinguishing feature of the product is its learning capability: Kosmos is described as building on an organization's experimental history, decision patterns, and proprietary scientific data. The company also emphasizes that the platform remains model agnostic, allowing it to leverage the best frontier models as new state-of-the-art models emerge. This positions Edison Scientific in the emerging category of AI-native scientific research platforms that combine large language models with domain-specific scientific workflows. The company states that it is trusted by leading biopharma organizations and academic institutions. Its marketing materials include testimonials from industry figures such as Whit Bernard, Managing Partner at Population Health Partners and CEO of Metsera, and Patrick Mayes, Executive Vice President and Chief Scientific Officer, who highlight the potential of AI to evaluate more opportunities, move faster, and enhance result interpretation through feedback loops. Edison Scientific operates in the competitive and rapidly evolving field of AI for drug discovery and development, where it competes with other computational biology and AI research platforms. The company is privately held, and its headquarters location in San Francisco places it within a major hub for biotechnology and artificial intelligence. As of the available evidence, specific details such as founding year, founders, funding, and executive leadership beyond the quoted testimonials are not publicly documented in the supplied sources.

Edison Scientific Inc. is a privately held artificial intelligence company based in San Francisco, California, United States. The company has developed an AI platform called Kosmos, which it markets as "The AI Scientist for R&D." The platform is designed to accelerate the full lifecycle of research and development, from hypothesis generation to regulatory approval, and is targeted at biopharma organizations and academic institutions. The available evidence does not specify the company's founding date, founders, or early history. What is documented is its product positioning and capabilities. Kosmos is described as an AI system that can read literature, analyze data, generate hypotheses, steer investigations mid-run, branch hypotheses, and execute scientific workflows autonomously. It is intended to support the full lifecycle of drug development, executing workflows from target identification through clinical development and filing. The platform is designed to embed in scientists' workstreams, collaborating through Slack, Teams, and email while advancing investigations and surfacing findings. It also learns from an organization's experimental history, decision patterns, and proprietary scientific data. A key architectural principle is model agnosticism, allowing the platform to leverage the best frontier models as new state-of-the-art models emerge. Edison Scientific states that its platform is trusted by leading biopharma organizations and academic institutions. Testimonials on its website include Whit Bernard, Managing Partner at Population Health Partners and CEO of Metsera, who speaks to the challenge of scale in building biotech companies and the role of AI in evaluating more opportunities and moving faster. Patrick Mayes, Executive Vice President and Chief Scientific Officer, highlights how systems that learn from experimental and clinical data can enhance result interpretation and create a feedback loop that boosts speed and quality in future programs. The company operates in the competitive field of AI for drug discovery and development, where it joins a growing ecosystem of computational biology and AI research platforms. As a private company headquartered in San Francisco, it is situated within a major hub for both biotechnology and artificial intelligence. Further details about its corporate history, funding, and leadership are not available in the supplied evidence.

AI platform for scientific R&D, positioned as "The AI Scientist for R&D" that accelerates the full lifecycle of research and development from hypothesis to approval.

• Kosmos

  An AI scientist for R&D that accelerates the full lifecycle of research and development, from hypothesis to approval. It reads literature, analyzes data, generates hypotheses, steers investigations mid-run, branches hypotheses, and executes scientific workflows autonomously. It supports the full lifecycle of drug development from target identification through clinical development and filing, embeds in scientists' workstreams via Slack, Teams, and email, learns from organizational knowledge, and remains model agnostic.

1. 1Edison Scientific | The AI Platform for scientific R&Dedisonscientific.com
2. 2Edison Scientific Inc. (United States) - Wikidatawikidata.org